Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Real world persistence of multiple sclerosis disease modifying therapies

Tallantyre, Emma C. ORCID:, Dobson, Ruth, Froud, Joseph L. J., St John, Frederika A., Anderson, Valerie M., Arun, Tarunya, Buckley, Lauren, Evangelou, Nikos, Ford, Helen L., Galea, Ian, George, Sumi, Gray, Orla M., Hibbert, Aimee M., Hu, Mo, Hughes, Stella E., Ingram, Gillian, Kalra, Seema, Lim, Chia-Hui, Mathews, Joela T. M., McDonnell, Gavin V., Mescall, Naomi, Norris, Sam, Ramsay, Stephen J., Rice, Claire M., Russell, Melanie J., Shawe-Taylor, Marianne J., Williams, Thomas E., Harding, Katherine E. and Robertson, Neil P. ORCID: 2024. Real world persistence of multiple sclerosis disease modifying therapies. European Journal of Neurology 10.1111/ene.16289

[thumbnail of Euro J of Neurology - 2024 - Tallantyre - Real‐world persistence of multiple sclerosis disease‐modifying therapies.pdf]
PDF - Published Version
Available under License Creative Commons Attribution.

Download (2MB) | Preview


Background and purpose Treatment persistence is the continuation of therapy over time. It reflects a combination of treatment efficacy and tolerability. We aimed to describe real-world rates of persistence on disease-modifying therapies (DMTs) for people with multiple sclerosis (pwMS) and reasons for DMT discontinuation. Methods Treatment data on 4366 consecutive people with relapse-onset multiple sclerosis (MS) were pooled from 13 UK specialist centres during 2021. Inclusion criteria were exposure to at least one MS DMT and a complete history of DMT prescribing. PwMS in blinded clinical trials were excluded. Data collected included sex, age at MS onset, age at DMT initiation, DMT treatment dates, and reasons for stopping or switching DMT. For pwMS who had received immune reconstituting therapies (cladribine/alemtuzumab), discontinuation date was defined as starting an alternative DMT. Kaplan–Meier survival analyses were used to express DMT persistence. Results In 6997 treatment events (1.6 per person with MS), median time spent on any single maintenance DMT was 4.3 years (95% confidence interval = 4.1–4.5 years). The commonest overall reasons for DMT discontinuation were adverse events (35.0%) and lack of efficacy (30.3%). After 10 years, 20% of people treated with alemtuzumab had received another subsequent DMT, compared to 82% of people treated with interferon or glatiramer acetate. Conclusions Immune reconstituting DMTs may have the highest potential to offer a single treatment for relapsing MS. Comparative data on DMT persistence and reasons for discontinuation are valuable to inform treatment decisions and in personalizing treatment in MS.

Item Type: Article
Date Type: Published Online
Status: In Press
Schools: Medicine
MRC Centre for Neuropsychiatric Genetics and Genomics (CNGG)
Publisher: Wiley Open Access
ISSN: 1351-5101
Date of First Compliant Deposit: 3 April 2024
Date of Acceptance: 14 March 2024
Last Modified: 04 Apr 2024 13:55

Actions (repository staff only)

Edit Item Edit Item


Downloads per month over past year

View more statistics